1-[(2,4-dichlorophenyl)(p-tolyl)methyl]piperazine | 514170-15-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(2,4-dichlorophenyl)(p-tolyl)methyl]piperazine
• 英文别名: 1-[(2,4-Dichlorophenyl)-(4-methylphenyl)methyl]piperazine
• CAS: 514170-15-1
• 化学式: C₁₈H₂₀Cl₂N₂
• 分子量: 335.276
• InChiKey: RKZWGAXEWGDRLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[(2,4-dichlorophenyl)(p-tolyl)methyl]piperazine 、 环己基异氰酸酯 以 二氯甲烷 为溶剂， 以90%的产率得到N-cyclohexyl-4-[(2,4-dichlorophenyl)(p-tolyl)methyl]piperazine-1-carboxamide
  参考文献：
  名称：

  Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach

  摘要：

  The present study describes the identification via privileged structure-based approach of the benzhydrylpiperazine moiety as a potential scaffold to develop novel CB1 receptor modulators. Efficient structural optimization of the initial four hit compounds led to a high quality lead series, represented by compound 6c. Compound 6c is a highly potent and selective CB1 receptor inverse agonist that is able to reduce body weight in diet-induced obese Sprague-Dawley rats. The preparation of privileged structure-based library, the progression from hit to lead, the structure-activity relationships in the lead series and in vitro and in vivo activity of compound 6c are discussed. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.12.018
• 作为产物：
  描述：

  哌嗪 、 2,4-Dichloro-1-[chloro-(4-methylphenyl)methyl]benzene 以 乙腈 为溶剂， 生成 1-[(2,4-dichlorophenyl)(p-tolyl)methyl]piperazine
  参考文献：
  名称：

  Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach

  摘要：

  The present study describes the identification via privileged structure-based approach of the benzhydrylpiperazine moiety as a potential scaffold to develop novel CB1 receptor modulators. Efficient structural optimization of the initial four hit compounds led to a high quality lead series, represented by compound 6c. Compound 6c is a highly potent and selective CB1 receptor inverse agonist that is able to reduce body weight in diet-induced obese Sprague-Dawley rats. The preparation of privileged structure-based library, the progression from hit to lead, the structure-activity relationships in the lead series and in vitro and in vivo activity of compound 6c are discussed. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.12.018

文献信息

• Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach
  作者：Tao Meng、Jue Wang、Hongli Peng、Guanghua Fang、Min Li、Bing Xiong、Xin Xie、Yongliang Zhang、Xin Wang、Jingkang Shen

  DOI：10.1016/j.ejmech.2009.12.018

  日期：2010.3

  The present study describes the identification via privileged structure-based approach of the benzhydrylpiperazine moiety as a potential scaffold to develop novel CB1 receptor modulators. Efficient structural optimization of the initial four hit compounds led to a high quality lead series, represented by compound 6c. Compound 6c is a highly potent and selective CB1 receptor inverse agonist that is able to reduce body weight in diet-induced obese Sprague-Dawley rats. The preparation of privileged structure-based library, the progression from hit to lead, the structure-activity relationships in the lead series and in vitro and in vivo activity of compound 6c are discussed. (C) 2009 Elsevier Masson SAS. All rights reserved.